

Aggrastat[®] (tirofiban) – First-time generic

- On May 30, 2023, Nexus launched an [AP-rated](#) generic version of Medtronic's [Aggrastat \(tirofiban\)](#) 5 mg/100 mL injection.
 - In addition, Gland received FDA approval of an [AP-rated](#) generic version of Aggrastat 12.5 mg/250 mL injection on April 8, 2021, and Eugia received FDA approval of [AP-rated](#) generic versions of Aggrastat 5 mg/100 mL and 12.5 mg/250 mL injections on May 1, 2023. Launch plans for these generics are pending.
- Aggrastat is approved to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.